top_10_image_2_9’s top 10 news stories of the week

pharmafile | January 15, 2021 | News story | Medical Communications COVID-19’s most popular stories this week include the use of two new, potentially life-saving treatments for on COVID-19 patients, and the beginning of UK trials for another. Pfizer has said its coronavirus vaccine is effective against the new variants identified in the UK and South Africa, and the EMA has revealed that COVID-19 vaccine data stolen by hackers was leaked on the internet.

In other news, Eli Lilly has announced positive Phase II results for its Alzheimer’s medicine, ViiV’s HIV treatment for children has been granted EU approval, and Pfizer has invested $25 million in a bioscience company focused on treatments for immune-mediated diseases.

 1. Trial of potential new COVID-19 treatment begins in UK – Published 13/01/2021

A large-scale trial of a new COVID-19 treatment to prevent severe illness in coronavirus patients has begun in the UK.

2. COVID-19 vaccine data leaked online by hackers, EMA says – Published 14/01/21

The EMA has confirmed that data relating to COVID-19 medicines and vaccines that was stolen by hackers in December have been leaked on the internet.

3. Eli Lilly’s Alzheimer’s drug slows clinical decline in Phase II trial – Published 11/01/21

Eli Lilly’s donanemab has shown significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer’s disease compared to placebo in results from its Phase II TRAILBLAZER-ALZ study.

4. Pfizer invests $25m in Vedanta BioSciences’ IBD treatment – Published on 13/01/21

Pfizer has invested $25 million in Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases, as part of the Pfizer Breakthrough Growth Initiative.

5. Arthritis drugs could save lives of COVID-19 patients, study finds – Published 08/01/21

Two drugs used to treat rheumatoid arthritis could cut COVID-19 hospital stays by as much as 10 days, and save the lives of one in 12 intensive care patients with coronavirus, new research has found.

6. Sanofi to acquire Kymab for $1.1bnPublished on 11/01/21

Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion.

7. Roche’s influenza drug Xofluza gets EU approvalPublished on 11/01/21

The European Commission (EC) has approved Roche’s Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above.

8. Pfizer’s COVID-19 vaccine protects against variants, research showsPublished on 08/01/21

Pfizer’s COVID-19 vaccine is effective against the two fast-spreading variants of the virus that emerged in the UK and South Africa, according to new research by the company.

9. ViiV gets EU approval for children’s HIV treatmentPublished on 13/01/21

ViiV Healthcare, the global specialist HIV company, has received marketing authorisation from the European Commission for Tivicay (dolutegravir) 5mg dispersible tablets, which are used in combination with other antiretroviral agents for the treatment of HIV in children.

10. Seven mass vaccination sites open in EnglandPublished on 11/01/21

Seven mass vaccination centres have opened in England today as the government works to vaccinate as many people as possible by February.

Related Content

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …

The NIH’s RECOVER initiative could lead to the first official treatment for long COVID-19

As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials …


Moderna files for FDA authorisation for updated COVID-19 vaccine

Biotechnology company Moderna has announced that it has completed submission of a regulatory application to …

Latest content